| 翻訳と辞書 |
LGX818
Encorafenib, also known as LGX818 is a drug candidate for the treatment of melanoma with the V600E mutation in the B-RAF kinase. The substance is being developed by Novartis, is in phase III clinical trials, and was disclosed at the spring 2013 American Chemical Society meeting in New Orleans.〔C. Drahl, Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA, 2013, http://cenblog.org/the-haystack/2013/04/liveblogging-first-time-disclosures-of-drug-structures-from-acsnola/〕〔http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011023773〕〔http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2011025927〕
== Clinical trials ==
Several clinical trials of LGX818, either alone or in combinations with the MEK inhibitor MEK162,〔http://www.cancer.gov/clinicaltrials/search/view?cdrid=728588&version=HealthProfessional&protocolsearchid=11645832〕 CDK4 inhibitor LEE011〔http://www.cancer.gov/clinicaltrials/search/view?cdrid=745927&version=HealthProfessional&protocolsearchid=11645832〕 are being run. The initial results are encouraging〔http://www.novartis.com/downloads/investors/event-calendar/2012/6-bridging-science-and-patients.pdf〕 and were presented at ASCO 2013.〔http://www.arraybiopharma.com/_documents/Publication/PubAttachment571.pdf Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors〕 As a result of a successful Phase Ib/II trials, Phase III trials are currently being initiated.〔http://clinicaltrials.gov/ct2/show/NCT01909453?term=LGX818&rank=1 Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma (COLUMBUS)〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「LGX818」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|